Burden of Cervical Cancer in Tanzania
Recruitment status was: Not yet recruiting
Cervical cancer screening is a worldwide problem especially in the developing world of which Tanzania belongs. It is diagnosed late in the third world because there are no diagnostic facilities and resource people. It occurs in the age groups between 40 and above and therefore affects the productive age of the community. It is well known that women generally are the backbone of every community and specifically in the developing countries.
The objective of this research is to analyze and quantify the burden of cervical cancer disease in the community. It will research the interpersonal and socioeconomic issues associated with cervical cancer disease in the family.
-Socioeconomic Burden of Disease
|Study Design:||Observational Model: Cohort
Time Perspective: Cross-Sectional
|Official Title:||Survey Assessment and Projection of the Social and Economic Burdens of Cervical Cancer in Tanzania|
- Socioeconomic burden to households [ Time Frame: 12 months ]
- share of household consumption attributable to medical care (hospitals, dispensaries, etc.)
- monthly household income (work hours, income sources, changes in the type or amount)
- child school attendance, nutrition (school days missed in past week, meals eaten, source of proteins on day prior to interview)
- Projection of economic impact on community [ Time Frame: 12 months ]Combine rates of cervical cancer with the age and gender distribution in the Kilimanjaro Region (Tanzania Census), distribution of cancer stages, and primary outcomes from the study cohort to estimate of total medical expenses, income losses, and school days missed due to cervical cancer.
|Study Start Date:||October 2010|
|Estimated Study Completion Date:||December 2012|
|Estimated Primary Completion Date:||October 2012 (Final data collection date for primary outcome measure)|
Terminal cervical cancer- not treatable
Early cervical cancer = meaning treatable with hysterectomy.
Advanced cervical cancer- treatable with chemotherapy and/or radiation.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01177345
|Contact: Olola Oneko, MMED||255 754 478 email@example.com|
|Kilimanjaro Christian Medical Center||Not yet recruiting|
|Moshi, Kilimanjaro Region, Tanzania|
|Principal Investigator: Olola Oneko, MMED|